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Objective. To assess the impact of a pharmacy beneﬁt change on mail order phar-
macy (MOP) uptake.
Data Sources/Study Setting. Race-stratiﬁed, random sample of diabetes patients in
an integrated health care delivery system.
Study Design. In this natural experiment, we studied the impact of a pharmacy bene-
ﬁt change that conditionally discounted medications if patients used MOP and prepaid
two copayments. We compared MOP uptake among those exposed to the beneﬁt
change (n = 2,442) and the reference group with no beneﬁt change (n = 8,148), and
estimated differential MOP uptake across social strata using a difference-in-differences
framework.
Data Collection/Extraction Methods. Ascertained MOP uptake (initiation among
previous nonusers).
Principal Findings. Thirty percent of patients started using MOP after receiving the
beneﬁt change versus 9 percent uptake among the reference group (p < .0001). After
adjustment, there was a 26 percentage point greater MOP uptake (beneﬁt change
effect). This beneﬁt change effect was signiﬁcantly smaller among patients with inade-
quate health literacy (15 percent less), limited English proﬁciency (14 percent less), and
among Latinos and Asians (24 and 16 percent less compared to Caucasians).
Conclusions. Conditionally discounting medications delivered by MOP effectively
stimulated MOP uptake overall, but it unintentionally widened previously existing social
gaps in MOP use because it stimulated less MOP uptake in vulnerable populations.
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Mail order pharmacies (MOPs) dispense medications by mail to the patient’s
home, offering convenience and eliminating access barriers (e.g., time, mobil-
ity, transportation), the beneﬁts of which may be compounded for patients
using multiple medications (Choudhry et al. 2011). Currently, one-third of all
chronic disease prescriptions in the United States are dispensed by mail
(Wroblewski et al. 2005). We have previously demonstrated better adherence
(Duru et al. 2010), better LDL-C control (Schmittdiel et al. 2011), and no
substantive safety concerns (Schmittdiel et al. 2013) among diabetic patients
using MOPs. Better adherence among those using MOPs has been reported
in other studies as well (Devine, Vlahiotis, and Sundar 2010; Zhang et al.
2011; Visaria, Frazee, and Devine 2012).
Compared to walk-in pharmacies, MOPs can also be cost-saving for the
health plan, depending on differential wastage rates between the two delivery
modes, the cost of increased drug utilization, and the size of any MOP incen-
tives (Carroll et al. 2005; Carroll 2006; Valluri et al. 2007; Devine, Vlahiotis,
and Sundar 2010). The World Health Organization recommends seeking
effective and low-cost, structural (system-level) approaches to improving
adherence as an alternative to the frequently expensive, individual-level inter-
ventions (Sabate 2003). Financial incentives for MOPs may represent such a
system-level approach if they increase the use of MOPs and secondarily
improve adherence and health outcomes.
However, structural changes can simultaneously improve popula-
tion-level quality metrics, while also increasing social inequalities in
health access and outcomes. We have previously reported lower use of
MOPs among minorities and those living in deprived neighborhoods
(Duru et al. 2010). While MOP use has been increasing steadily over the
past two decades (Carroll et al. 2005), underuse in vulnerable groups has
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been observed at Kaiser Permanente Northern California (KPNC) since
MOPs were introduced in 1999 (unpublished data). For example, in
2000, the prevalence of MOP use was 11 percent in Latinos, 12 percent
in African Americans and Filipinos, 20 percent in Asians, and 24 percent
in Caucasians. A decade later, in 2010, MOP use grew considerably, but
it still lagged substantially in minorities: 37 percent in Latinos and Afri-
can Americans, 46 percent in Filipinos, 63 percent in Asians, and 65 per-
cent in Caucasians. It remains unknown whether and how ﬁnancial
incentives might impact disparities in MOP use (Trinacty et al. 2009).
We studied a natural experiment which included a pharmacy beneﬁt
change that increased cost sharing but promoted the use of MOPs by
discounting medications (i.e., reducing the increase in out-of-pocket costs)
if patients prepaid two copayments and reﬁlled using MOPs. We evalu-
ated the following: (1) the overall effect of rolling out the beneﬁt change
on subsequent uptake of MOPs for dispensing of cardiometabolic medi-
cations among patients with diabetes, and (2) whether the rollout’s effect
on MOP uptake was uniform across social strata (deﬁned by ethnicity,
educational attainment, household income, English proﬁciency, or health
literacy).
METHODS
Setting
This study was conducted in KPNC, an integrated, health care delivery sys-
tem that provides medical care to ~3 million members (~30 percent of the
population of the catchment, with ethnic and socioeconomic distributions sim-
ilar to the general population, although fewer very poor or rich members)
(Gordon and Kaplan 1991).
KPNC health plan pharmacy beneﬁts are available only through
KPNC’s ~120 community pharmacies or, since 1999, via MOPs. Although
most new prescriptions are ﬁrst dispensed at community pharmacies (Valluri
et al. 2007), KPNC patients may also ﬁll new prescriptions by mail, with tele-
phone access to a pharmacist who can answer medication-related questions
after completing a simple enrollment process (by mail, phone, or website).
Unlike some MOP systems, KPNC patients must request (by mail, phone, or
website) each MOP dispensing and provide payment in advance (by credit
card or check) before the medication is mailed (no automatic reﬁlls). Medica-
tions usually arrive within 1 week.
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Intervention
Prior to January 1, 2006, the standard KPNC drug plan for all subjects
required one copayment per dispensing (regardless of days’ supply or
mode of delivery). Effective January 1, 2006, all individual Medicare
Senior Advantage members and select commercial and employer groups
were changed to a new, less generous drug beneﬁt package (more cost
sharing), which also included an incentive, in the form of a prepayment
discount, to use MOPs. The change in drug beneﬁt was not a matter of
individual choice but rather based on employer group contracts.
Impacted health plan members, which typically included more socially
vulnerable subjects, were mailed an announcement describing the beneﬁt
changes and the MOP discount; originally in English only, translated ver-
sions of the announcement were available in the following year. The new
beneﬁt provided a 1-, 2-, or 3-month supply at community pharmacies at
a charge of one, two, or three copayments, respectively. Alternatively,
patients could use MOPs and receive a 1-month supply for one copay-
ment or use the prepaid discount which incentivized use of MOPs by
receiving a 3-month supply for two copayments (Figure 1). Thus, a
patient who was willing and able to prepay two copayments would
receive a 100-day supply from the MOP compared with a 60-day supply
from the walk-in pharmacy (i.e., 40 extra days’ supply for using MOPs).
To illustrate, consider a scenario among patients whose beneﬁts contract
had stipulated a $10 copayment per dispensing (typically, a 3-month supply);
that is, prior to the January 1, 2006 beneﬁt change, all patients would have
been charged $10 for each dispensing of a standard 3-month supply, regard-
less of whether they used a walk-in pharmacy or MOP. Among those patients
who had no change in beneﬁts, that copayment remained unaltered after Janu-
ary 1, 2006. In contrast, patients who had a beneﬁt change would now pay $10
for each 1-month supply; however, they could get a better deal if they used the
MOP and requested three 1-month supplies. That is, patients with the beneﬁt
change who obtained their medications via walk-in pharmacy would pay $10
for each 1-month supply. However, if they chose to use MOPs, they would
pay $10 for each 1-month supply, or $20 for a 3-month supply. Thus, the mail
order prepayment discount permitted them to pay one copayment less ($10 in
this scenario) for a 3-month supply compared to using a walk-in pharmacy.
Thus, their cost share for a 3-month supply changed from $10 (before the
change) to $30 for medications obtained via walk-in pharmacy or $20 for
medications obtained via MOPs. Therefore, the prepayment discount to use
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MOPs did not offset the increase in cost sharing for those switched to the new,
less generous beneﬁt.
Participants
Study subjects were drawn from a cohort of 20,188 adults who were respon-
dents (62 percent response rate) in the Diabetes Study of Northern California
(DISTANCE) Survey, an ethnically stratiﬁed, random sample of diabetes
members identiﬁed prior to January 1, 2005 (Moffet et al. 2008). The DIS-
TANCE survey was offered in English, Spanish, Mandarin, Cantonese, or
Tagalog and included a wide range of social factors that we hypothesized to be
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Figure 1: Impact of the January 1, 2006, Beneﬁt Change for Select Patients
on Their Cost Sharing and Duration of Supply Dispensed for Patients Obtain-
ing Their Medications via Walk-in versus Mail Order Pharmacy. (Note that
the copayment* per dispensing varies—typically from $5 to $15 per copay-
ment—and depends on the individual’s contract)
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associated with social disparities in health care use and outcomes. To study the
effect of the pharmacy beneﬁt change among nonusers of MOPs, we limited
the study population to diabetes patients not offered incentives to use MOPs
nor usingMOPs prior to baseline, and dispensed at least one of the cardiomet-
abolic medications used as primary treatment for diabetes patients (antiglyce-
mic, antihypertensive, or lipid-lowering). Thus, we excluded the 5,216
subjects who used MOPs during the 12 months prior to baseline ( January 1,
2006); we also excluded 1,131 subjects not dispensed any cardiometabolic
medication during the 2 years prior to baseline ( January 1, 2004–December
31, 2005) or during the year after baseline ( January 1, 2006–December 31,
2006), and 3,251 who either lacked continuous Kaiser membership or a stan-
dard pharmacy beneﬁt contract throughout the observation window. This
yielded an analytic sample of 10,590 subjects, of which 2,442 (23 percent) had
a beneﬁt change and 8,148 (77 percent) had no change, serving as the reference
group.
Outcomes and Follow-Up
Initiation of MOP use (“uptake”) was deﬁned as having at least one MOP dis-
pensing for a cardiometabolic medication in the 12 months after baseline
(among previous nonusers). Our goal was to estimate the effect of the phar-
macy beneﬁt change on MOP uptake overall and across social groups deﬁned
by self-reported ethnicity, educational attainment, annual income, self-
reported ﬁnancial hardship (self-reported difﬁculties purchasing needed medi-
cations [Chien-Wen et al. 2002], medical supplies, or food [Ross and Wu
1995] due to insufﬁcient funds), limited English proﬁciency (always or often
having problems speaking or reading English), and a validated measure of
health literacy (problems understanding health education materials or instruc-
tions; Chew, Bradley, and Boyko 2004).
Statistical Analysis
We used a difference-in-differences (DID) framework to study the impact
of the beneﬁt change on mail order uptake (“beneﬁt change effect”). This
beneﬁt change effect was then contrasted (again using DID) across social
groups by estimating the adjusted, absolute difference between the beneﬁt
change effect for any given social group and the reference social category
(e.g., beneﬁt change effects for African American minus beneﬁt change
effects for Caucasian); this estimate was called the “effect difference.”
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DID is a quasi-experimental approach used to study change in an out-
come before and after an intervention, after “netting out” the background
change in rates due to effect of secular time trends and aging on that
same outcome identiﬁed in a reference group who was not affected by
the intervention (Campbell and Stanley 1963; Meyer 1995). Regression
to the mean is not a concern given both exposed and reference group
have the identical starting point (none are MOP users at baseline). In the
context of this study, the beneﬁt change effect on mail order uptake was
estimated by the uptake during the year following the beneﬁt change
after subtracting the background secular time trends estimated by MOP
uptake in those not experiencing the beneﬁt change (reference group).
DID rests on the assumption that the unobservable (i.e., counterfactual)
outcome in the exposed group, if they had not been exposed to the interven-
tion, would be qualitatively similar to the observable outcome in the unex-
posed reference group. That is, if the group exposed to the changes in the
beneﬁts had (counterfactually) not been exposed to those beneﬁt changes,
then we assume their MOPuptake would be similar to that observed in the ref-
erence group. We examined the validity of the DID assumption by evaluating
the MOP uptake in 2005 (the year prior to the exposure) among subjects who
had no MOP use as of January 1, 2006, selecting the “soon-to-be-exposed”
subjects who would receive the beneﬁt change in January 1, 2006, and com-
paring them to the remaining subjects (i.e., no beneﬁt change in 2006) who
made up the reference group. The 2005 rates of uptake of MOP in these two
groups prior to the implementation of the new beneﬁt design were similar,
although not identical. There was a modestly larger MOP uptake among those
who would later receive a change in beneﬁts versus the reference group (1.38
vs. 1.04 percentage points per month, respectively). Although the 2005 popu-
lation used for this test of assumptions was not identical to the population used
for the ﬁnal analysis (as we excluded those who started using MOPs during
2005 prior to the January 1, 2006 baseline), the qualitatively similar uptake
suggests that the DID assumption should be reasonable. While selection into
groups receiving the different beneﬁt packages could introduce bias in the esti-
mate of the beneﬁt effect, this bias is assumed uniform across social groups
and thus should not impact the estimate of beneﬁt effect differences across
social groups in a substantive way. However, while we present the quantitative
DID results below, we will interpret those ﬁndings strictly as qualitative given
this is an evaluation of a natural experiment that rests on unobservable
assumptions.
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We addressed potential confounding from measured and unmeasured
risk factors by using each treated group as its own control, comparing poten-
tially confounding risk factors before versus after the beneﬁt change use dur-
ing our study, and by controlling for demographic and clinical differences
between those with the beneﬁt change versus the reference group. Those pre-
valent differences were accounted for using a marginal structural modeling
(MSM) approach based on the counterfactual theory of causality (Robins
1999; Mortimer et al. 2005). The adjusted MSMmodels were weighted using
a propensity score method called inverse probability of treatment weights
(IPTW). The IPTW were derived from a pooled logistic regression model
(R2 = 77 percent): beneﬁt change (yes/no) was regressed on baseline age,
pharmacy copay for generic and brand medications, Medicare indicator,
pharmacy beneﬁt deductible indicator, pharmacy beneﬁt business line (e.g.,
large employer group, small employer group, strategic group), ethnicity,
income, education, limited English proﬁciency, inadequate health literacy, or
ﬁnancial hardship. This weighting aligns the distribution in the comparison
cohort of the variables used in the beneﬁt change-probability model to match
the distribution in the exposed group who experienced the beneﬁts change.
These estimates are unconfounded by the above adjustment variables under
the assumption that the model is speciﬁed correctly. Models were further
weighted to account for survey nonresponse (Horvitz and Source 1952) and
the nonproportional sampling fractions (complex survey design). We esti-
mated the adjusted, absolute beneﬁt change effect (difference-in-differences)
by specifying modiﬁed Poisson regression models (Zou 2004) with robust
standard errors and an identity link function (Cheung 2007). Conﬁdence inter-
vals were estimated using bootstrapping. We also conducted sensitivity analy-
sis after excluding the 6 percent (n = 991) of patients whose expenditures
exceeded that covered by Medicare Part D (i.e., those reaching the coverage
limit or “doughnut hole”) during follow-up because ﬁnancial incentives to use
MOPs would no longer be relevant while in the gap.
RESULTS
Subject Characteristics
The mean age of the subjects was 60 years, 50 percent were women, 80 per-
cent minorities, 12 percent had limited English proﬁciency, and 46 percent
had inadequate health literacy (Table 1). Twenty-one percent had annual
income <$25,000 and 38 percent self-reported difﬁculties paying for medica-
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tions. Compared to the reference group, subjects who had a pharmacy beneﬁt
change had lower educational attainment, lower income, greater ﬁnancial
hardships, and more likely to have limited English proﬁciency, inadequate
Table 1: Characteristics (Unadjusted*) of the 10,590 KPNC Patients Who
Had Not Used a Mail Order Pharmacy Prior to Baseline Date of Pharmacy
Beneﬁt Change ( January 1, 2006)
Patient Characteristics
All
(n = 10,590)
Pharmacy Beneﬁt Change in 2006
Yes
(n = 2,442)
No
(n = 8,148)
p-value for
Unadjusted
Difference†
Demographics
Female 5,332 (50.4) 1,309 (53.6) 4,023 (49.4) .0002
Mean age (in years) (SD) 59.7 (10.1) 64.8 (10.1) 58.2 (9.6) <.0001
Race/ethnicity
African American 2,126 (20.1) 345 (14.1) 1,781 (21.9) <.0001
Asian 1,101 (10.4) 284 (11.6) 817 (10.0)
Caucasian 1,955 (18.5) 546 (22.4) 1,409 (17.3)
Filipino 1,398 (13.2) 232 (9.5) 1,166 (14.3)
Latino 2,053 (19.4) 618 (25.3) 1,435 (17.6)
Multiracial 1,164 (11.0) 251 (10.3) 913 (11.2)
Other/unknown 793 (7.5) 166 (6.8) 627 (7.7)
Education
No degree 1,839 (17.8) 694 (29.5) 1,145 (14.3) <.0001
High school/GED 3,086 (30.0) 730 (31.0) 2,365 (29.5)
Some college 2,613 (25.3) 503 (21.4) 2,110 (26.4)
College graduate 2,808 (27.1) 427 (18.1) 2,381 (29.8)
Annual income (in thousands)
<$25K 1,891 (21.4) 906 (45.6) 985 (14.4) <.0001
$25K–$49K 2,709 (30.6) 584 (29.4) 2,125 (31.0)
$50K–$79K 2,176 (24.6) 278 (14.0) 1,898 (27.7)
≥$80K 2,074 (23.4) 219 (11.0) 1,855 (27.0)
Reported difﬁculties paying for
medications
661 (7.9) 262 (14.0) 399 (6.2) <.0001
Reported difﬁculties paying for
food
2,603 (26.7) 732 (32.8) 1,871 (24.8) <.0001
Reported difﬁculties paying for
medical supplies
403 (5.7) 142 (9.2) 261 (4.8) <.0001
Any ﬁnancial hardship (for
food, Rx, or med supplies)
2,969 (38.4) 875 (49.1) 2,094 (35.2) <.0001
Limited English proﬁciency 1,086 (12.3) 394 (19.8) 692 (10.1) <.0001
Inadequate health literacy 3,297 (46.3) 909 (57.7) 2,388 (43.1) <.0001
Mean home to local pharmacy
distance inmiles (SD)
6.5 (9.2) 7.0 (10.7) 6.4 (8.8) .005
*n (%) unless otherwise speciﬁed; column percentages shown.
†p-value for chi-square test for categorical variables and t-test for continuous variables.
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health literacy, and higher out-of-pocket costs for their cardiometabolic medi-
cations in the year prior to baseline. Prior to baseline, the average daily cost
for medications in the beneﬁt change versus reference groups was $0.23 ver-
sus $0.15, and the average out-of-pocket cost per dispensing was $13.65 versus
$8.42, respectively (Table 2). Thus, relative to patients in the reference group,
those with the beneﬁt change were already incurring more cost sharing prior
to the change. The majority of subjects were dispensed 3-month supplies at
each ﬁll before and after the rollout of the beneﬁt change. As expected with
the introduction of a less generous cost-sharing arrangement, the proportion
dispensed 3-month supply at each ﬁll dropped slightly (from 85.5 percent
before the beneﬁt change to 83.1 percent after the beneﬁt change) among
those exposed to the beneﬁt change. For the reference group, the proportion
went up slightly during the pre- versus postperiod (from 88.4 to 90.7 percent).
MOP Uptake and Beneﬁt Change Effect
Among those who did not previously use MOP, 30 percent of diabetes
patients with the pharmacy beneﬁt change initiated use of MOP in the year
after the beneﬁt change, as compared to 9 percent of patients not receiving the
beneﬁt change (Table 3). The beneﬁt change effect was quantiﬁed by the abso-
lute difference in uptake between the beneﬁt change and reference groups,
which was a difference of 21 percentage points (95 percent CI: 19–23 percent)
in the crude model and 26 percentage points (CI: 22–30 percent) in the
adjustedmodel.
Vulnerable social groups had a substantially smaller MOP uptake over-
all and were less responsive to the discount. Among those with the beneﬁt
change, the beneﬁt change effect was higher among those with adequate
health literacy (35 percent percentage point greater uptake [95 percent CI:
27–42 percent]) compared to those with inadequate health literacy (20 percent
percentage point greater uptake [CI: 14–26 percent]), representing 15 percent-
age points (CI: 5 percent, 24 percent) effect difference. Similarly, the beneﬁt
change effect was 27 percent percentage point greater uptake (CI: 23–32 per-
cent) among English-speaking patients, while among those with limited Eng-
lish proﬁciency only 13 percent (CI: 6–21 percent), representing a 14 percent
(CI: 5 percent, 22 percent) point effect difference. There were also signiﬁcant
race-ethnic effect differences relative to Caucasians; Latinos and Asians had a
24 percent (CI: 14–33 percent) and 16 percent (CI: 0.1–30 percent) smaller
beneﬁt change effect. A smaller beneﬁt change effect was also observed among
those with lower annual income, self-reported ﬁnancial hardship, and fewer
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Table 2: Out-of-Pocket Costs and Utilization before and after Pharmacy
Beneﬁt Change among 10,590 KPNC Patients Who Had Not Used Mail
Order Pharmacy Prior to Baseline Date of Pharmacy Beneﬁt Change ( January
1, 2006)
Patient Characteristics
All
(n = 10,590)
Pharmacy Beneﬁt Change (before Weighting)
Yes
(n = 2,442)
No
(n = 8,148)
p-value for
Unadjusted
Difference§
12 months prior to baseline†
Per day per medication
cost,‡ for community
pharmacy ﬁlls, mean (SD)
$0.17 ($0.38) $0.23 (0.36) $0.15 ($0.38) <.0001
Total incurred cost per reﬁll,
for community ﬁlls,
mean (SD)
$9.62 ($8.53) $13.65 ($13.04) $8.42 ($6.11) <.0001
Days’ supply dispensed, for
community ﬁlls, mean (SD)
89 (16) 87 (18) 89 (15) <.0001
1-month supply dispensed 784 (7.4) 251 (10.3) 533 (6.5) <.0001
2-month supply dispensed 347 (3.3) 69 (2.8) 278 (3.4) .15
3-month supply dispensed 9,293 (87.8) 2,087 (85.5) 7,206 (88.4) <.0001
Total dispensings, for
community ﬁlls, mean (SD)
14.3 (7.8) 15.0 (7.8) 14.1 (7.8) <.0001
Cost sharing 12 months after
baseline†
Per day per medication cost,‡
for community
pharmacy ﬁlls, mean (SD)
$0.20 ($0.39) $0.35 ($0.48) $0.16 ($0.35) <.0001
Per day per medication cost,‡
for mail order pharmacy
ﬁlls, mean (SD)
$0.18 ($0.22) $0.28 ($0.26) $0.09 ($0.12) <.0001
Total incurred cost per reﬁll,
for community
ﬁlls, mean (SD)
$11.64 ($10.62) $21.33 ($15.27) $8.78 ($6.21) <.0001
Total incurred cost per reﬁll,
for mail order pharmacy
ﬁlls, mean (SD)
$15.97 ($16.93) $24.23 ($18.26) $7.77 ($10.27) <.0001
Days supply dispensed, for
Community pharmacy ﬁlls,
mean (SD)
88 (16) 83 (20) 90 (15) <.0001
Mail order pharmacy ﬁlls,
mean (SD)
91 (18) 95 (13) 87 (22) <.0001
1-month supply dispensed 801 (7.6) 336 (13.8) 465 (5.7) <.0001
2-month supply dispensed 246 (2.3) 48 (2.0) 198 (2.4) .18
3-month supply dispensed 9,417 (88.9) 2,030 (83.1) 7,387 (90.7) <.0001
continued
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years of education, albeit not statistically signiﬁcant after adjustment. There
were no substantive differences in our ﬁndings when rerunning the above
analyses after excluding the 991 members who lost Part D Medicare phar-
macy coverage during the observation window, and in separate models for
Medicare and non-Medicare subjects.
Sensitivity Analysis
To disentangle the effect of the ﬁnancial incentive for MOPs from a patient’s
choice of length of supply, we conducted a subanalysis in the 8,860 patients
who would beneﬁt from the incentive because they consistently ﬁlled 3-month
supply in the periods before and after the beneﬁt change. The adjusted MOP
uptake was 28 percentage points greater in those who received the beneﬁt
change compared to those with no change in beneﬁt (33 percent vs. 9 percent
uptake) (p < .0001). Thus, restricting to people who could beneﬁt from the
incentive because they always ﬁlled a 3-month supply yielded essentially the
same answer as the main analysis (which estimated a 26 percent increase in
MOP uptake). We then repeated that sensitivity analysis in the 741 patients
who would not beneﬁt from the incentive because they consistently ﬁlled less
than a 3-month supply during pre- and postperiods and detected no signiﬁcant
Table 2 Continued
Patient Characteristics
All
(n = 10,590)
Pharmacy Beneﬁt Change (before Weighting)
Yes
(n = 2,442)
No
(n = 8,148)
p-value for
Unadjusted
Difference§
Total dispensings, for
Community pharmacy
ﬁlls, mean (SD)
14.7 (8.1) 14.0 (8.8) 14.9 (7.9) <.0001
Mail order pharmacy
ﬁlls, mean (SD)
5.6 (5.5) 8.0 (6.3) 3.2 (3.3) <.0001
Insurance type
Part D group coverage (%) 1,454 (13.7) 22 (0.9) 1,432 (17.6) <.0001
Part D individual
coverage (%)
1,814 (17.1) 1,817 (74.3) 0
Non-Medicare coverage (%) 7,322 (69.1) 606 (24.8) 6,716 (82.4)
*n (%) unless otherwise speciﬁed; column percentages shown.
†2005 versus 2006 used for pre-post comparison of those not receiving the beneﬁt.
‡Per day medication cost equals the patient out-of-pocket cost divided by the days supply dis-
pensed.
§p-value for chi-square test for categorical variables and t-test for continuous variables.
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difference in uptake among those who did versus did not receive the beneﬁt
change.
DISCUSSION
We examined MOP uptake after a pharmacy beneﬁt change which included a
prepayment discount for use of MOP, while offering a less generous (more
cost sharing) pharmacy beneﬁt package. We observed a substantial stimulating
effect on MOPs uptake. In the year following the beneﬁt change, the MOP
uptake among previous MOP nonusers offered the prepayment discount to
use MOPs was a 26 percent points greater compared to those not offered the
discount. Given existing disparities in MOP use and the potential for MOPs to
improve convenience, medication adherence, and risk factor control, it is
important to understand the effects of beneﬁt changes and incentives on vul-
nerable populations. In general, patients behaved as price-sensitive consumers
and the discount greatly stimulated MOP uptake population-wide. However,
the effect of the beneﬁt change on MOPs was substantially smaller among
minorities, those with inadequate health literacy or limited English proﬁciency.
Since the introduction of MOPs at KPNC in 1999, minorities have con-
sistently lagged behind Caucasians in the uptake of MOPs and the reduced
minority response to the MOP discount perpetuated the disparities. Similar
patterns were observed in a recent study reporting that minorities or patients
with inadequate health literacy or lower educational attainment were less
likely to initiate use of a widely offered Internet-based patient portal even if
they had access to a computer (Sarkar et al. 2010, 2011). The disparities in
MOP use may have downstream impacts on disparities in medication adher-
ence and clinical outcomes. We have previously reported better adherence
(Duru et al. 2010) and better LDL-C control (Schmittdiel et al. 2011) among
diabetic patients using MOPs. Better adherence among those using MOPs has
been demonstrated in other studies (Devine, Vlahiotis, and Sundar 2010;
Zhang et al. 2011; Visaria, Frazee, and Devine 2012), although one study
(Khandelwal et al. 2011) had a null ﬁnding.
There are several possible explanations for these disparities in the effect
of beneﬁt changes. While one may expect greater price sensitivity in vulnera-
ble patients, the prepayment of the additional copayment required to receive
the incentive was possibly more of a barrier for the vulnerable groups. The
prepayment discount may have failed as an incentive if it was inadequately
communicated to or understood by patients. We observed signiﬁcantly lower
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uptake in those with inadequate health literacy, limited English proﬁciency,
and among the two ethnic groups (Latinos and Asians) with the greatest num-
ber of non-English-speaking patients compared to their respective reference
groups (i.e., those with adequate health literacy and proﬁcient in English, Cau-
casians). The reduced effect among patients with limited English proﬁciency is
not unexpected. The health plan mailed a written notice of the beneﬁt change
(in English) to all the beneﬁciaries in advance of beneﬁt design change but did
not distribute a Spanish version of the notice until the year after the study. No
other form of communication from the health plan was provided uniformly.
We should expect that some patients would have additional information pro-
vided via discussion with the pharmacist when patients inquired about charges
at the walk-in pharmacies. However, no subject-level data are available
regarding those discussions.
The lower effect among those with inadequate health literacy may be
attributable to difﬁculties navigating the complexities of the health system
(i.e., understanding the steps needed to initiate a mail order reﬁll); some
patients may prefer the regular face-to-face interactions with pharmacists if
they struggle with understanding written labels and medication instructions.
Poor literacy is often accompanied by poor numeracy (i.e., the inability to
understand and use numbers in daily life) which, though we did not assess this,
may make it difﬁcult for patients to weigh relative costs and beneﬁts of the
incentive (Cavanaugh et al. 2008; Rothman et al. 2008). Lower income indi-
viduals may lack a credit card and be unaware that MOPs can be requested
via a mail-in form with a check or be concerned about using a telephone or In-
ternet for credit card transactions. Some patients may be concerned about
having medications sent to a mailbox that may be vulnerable to theft.
The beneﬁt change offered a prepayment discount for MOPs such that
patients had a larger initial, out-of-pocket cost to obtain the discount (“pay to
play” design), representing a larger burden for vulnerable patients with limited
ﬁnancial resources, a barrier compounded for patients taking multiple medica-
tions. After the beneﬁt change, those receiving the less generous beneﬁt had a
substantial increase in cost sharing (e.g., $21.33 per reﬁll paid by those receiv-
ing the new beneﬁt vs. $8.78 in the reference group). Thus, the prepayment
burden was increased by the greater cost sharing. More price-sensitive patients
may simply have had insufﬁcient discretionary money or liquidity and were
limited by the two copayments needed to beneﬁt discount offer, or simply pre-
ferred “money in hand” over future savings provided by the incentive.
While the majority of subjects were dispensed 3-month supplies at each
ﬁll before and after the rollout of the beneﬁt change, the change to a less gener-
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ous cost-sharing arrangement also resulted in a slight decrease (2.4 percentage
points) in the proportion dispensed a 3-month supply at each ﬁll (from 85.5
percent before the beneﬁt change to 83.1 percent after the beneﬁt change)
among those exposed to the beneﬁt change. Our sensitivity analysis suggests
there was an incentive effect in members who were dispensed a 3-month sup-
ply before and after the beneﬁt rollout. Among the remaining minority of sub-
jects who ﬁlled less than a 3-month supply during pre- and postperiods, we
detected no signiﬁcant incentive effect; there was no signiﬁcant difference in
MOP uptake among those who did versus did not receive the beneﬁt change.
This sensitivity analysis suggests that the offered incentive will likely not stimu-
late MOP uptake among patients whose usual level of dispensing is less than a
3-month supply. It is important to note that 80–90 percent of health plan mem-
bers ﬁll a 3-month supply at each dispensing and stand to beneﬁt from the
incentive.
Some limitations and strengths should be noted. This is a study of a
nonrandomized exposure (beneﬁt changes), and although we used a rigorous
causal modeling approach (DID framework with marginal structural models)
to handle biases associated with observational studies, residual confounding
by measured or unmeasured variables is still a threat to validity. To isolate the
effect of the beneﬁt change on MOPs from expected secular changes in
MOPs, we netted out the MOP uptake among those who had no change in
beneﬁts (i.e., the reference group). A limitation of this analytic approach is
that there is no way to prove the validity of the DID assumption that the
MOP uptake in the reference group serves as a reasonable model for the
unobservable “background rates” of MOP uptake in the exposed group if
they were actually not exposed. Thus, we exercise caution when interpreting
the quantitative ﬁndings. Because we studied a cohort of nonusers, there were
no prior trends in uptake to guide our predictions of future changes in utiliza-
tion. However, given the magnitude of the quantitative differences in MOP
uptake (i.e., >3-fold greater MOP uptake in 2006 among those exposed to the
new beneﬁt vs. those not exposed) and the substantially smaller beneﬁt-
related uptake in socially vulnerable populations, we believe that the qualita-
tive interpretation of our ﬁndings regarding the uptake that is above and
beyond background is reasonable; the beneﬁt change with a prepayment dis-
count for MOP-stimulated MOP uptake, but less so in vulnerable popula-
tions. The stark differences in MOP uptake in patients receiving the
pharmacy beneﬁt change (vs. not) will likely diminish over time with grow-
ing acceptance for this new mode of medication delivery and as the number
of remaining nonusers decreases. Because this is observational research,
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interpreting the social differences in the impact of the beneﬁt change is com-
plicated given the exposed and reference groups differed on baseline social
characteristics, although the ﬁnal models adjusted for observed confounders.
The ideal reference group would have been patients who were switched to a
pharmacy beneﬁt offering a 1-month supply (rather than remaining on the 3-
month supply plan) without MOP incentives. No such beneﬁt structure
existed. Concerns of endogeneity arise if subjects can choose which level of
beneﬁts they were exposed to. However, during the time of this study, while
the generosity of beneﬁt coverage varied across employer group or Medicare,
patients receiving beneﬁts through any one of these contractors did not have
a choice of level of beneﬁt plan. All but 3 percent (n = 351) of our study sub-
jects acquired health plan coverage via employment or Medicare and thus
had no choice about the level of coverage. The adjusted model accounts for
differences in the generosity of beneﬁts by weighting for pharmacy beneﬁt
deductibles and pharmacy beneﬁt business line.
To simply report the MOP uptake in those experiencing the beneﬁt
change would overestimate the effect of the beneﬁt change given the secular
trends. We reduced that MOP uptake resulting from the beneﬁt change by the
background expected uptake observed in the reference group, after adjusting
for case mix differences. That said, the variation in uptake among different
social groups receiving the beneﬁt change (i.e., exposed) conveys the same
take home message; vulnerable subjects receiving the incentive were less
likely to initiate MOPs. For example, among those who did not use MOPs
prior to the beneﬁt change, 44 percent of Caucasians versus 21 percent of
Latino and African Americans initiated MOPs after receiving the beneﬁt
change. Although some of this MOP uptake would be expected due to secular
trends and thus not due to the beneﬁt change, the differential between social
groups is consistent with a beneﬁt change effect that differs is size across social
strata.
The pharmacy beneﬁt change combined the offer of a ﬁnancial incen-
tive, in the form of a prepayment discount, with a less generous pharmacy
beneﬁt plan. Those exposed to the beneﬁt change were switched from a
more generous baseline beneﬁt to a much less generous beneﬁt, and that
may have impacted the magnitude of the incentive effect on MOP uptake.
The ﬁnancial incentive is the most plausible explanation for the increased
MOP uptake. There is no obvious reason why charging patients more per
pill (due to the increased cost sharing imposed by the beneﬁt change) would
induce the large increase in use of MOPs that we observed overall or
induce vulnerable patients to be less likely to take advantage of the MOP
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incentive that reduces the cost per pill. On the contrary, to the extent that
vulnerable populations are more price sensitive, they might be expected to
be more likely to take advantage of the discount. Admittedly, we have no
data available to explain why subjects made their choices regarding whether
to initiate MOPs. Substantive changes in adherence could change the moti-
vation to use MOPs or sample composition. One of the strengths of this
study is that it was a natural experiment; the beneﬁt change was not subject
to patient choice or self-selection but was dependent on group contract
negotiations. Reverse causality is precluded also by the design’s temporal
ordering (i.e., pretest-posttest with controls), and regression to the mean is
not a concern given both exposed and reference group have the identical
starting point (none are MOP users at baseline).
This study suggests some policy-related lessons. Beneﬁt change
announcements using plain language in English and other languages should
be sent out prior to initiating the change. When both modes of medication
delivery are supported by a health delivery system, pharmacists and phar-
macy staff could verbally encourage the use of MOPs and explain any
potential cost savings associated with the MOPs to patients currently using
community pharmacies. Rather than requiring prepayment of an extra
copayment to receive the discount, a more uniform effect may be achiev-
able by restructuring the discount so that patients using MOPs receive a set
number of free days’ supply for each copayment. “Pay to play” designs such
as this may in the end act as a disincentive that overrides the beneﬁt of any
potential discounts for the patient in a way that differentially impacts vul-
nerable populations. While largely dictated by external forces (e.g., compet-
itive health plan markets, group purchaser and federal insurer demands,
rising cost of pharmaceuticals, and provision of health care), beneﬁt changes
present a difﬁcult policy dilemma for health care delivery systems given the
often competing economic and quality implications. In this case, the health
plan beneﬁt change simultaneously supported one quality improvement
goal (e.g., increase use of MOP) and potentially reduced the cost of phar-
macy operations, while competing with another (e.g., elimination of health
disparities). These ﬁndings further demonstrate the hazard of assuming uni-
form effects of innovations, interventions, or structural changes across
patient groups. While we expect that inequalities in use of MOP will shrink
as advantaged groups approach a ceiling and the disadvantaged groups
catch up, the pattern needs to be viewed in the larger context. Even if the
inequalities resulting from any given structural change eventually dissipate,
the constant stream of new structural changes can perpetuate or exacerbate
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existing inequalities if even small and temporary differences in health sys-
tem access are progressively introduced (see Phelan and Link’s theory of
“fundamental causes” [Phelan and Link 2005; Phelan et al. 2004]). To avoid
increasing existing social differences in utilization, early testing for hetero-
geneity in treatment effectiveness provides an important opportunity to pro-
actively design and tailor innovations, whether they be new beneﬁt models,
translation of interventions, or quality improvement efforts (Frohlich and
Potvin 2008; Varadhan et al. 2012).
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Figure S1. Directed Acyclic Graph (DAG) Used to Guide Our Develop-
ment of the Model of the Impact of Mail Order Incentives (MOIs) on Mail
Order Pharmacy (MOP) Use.
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